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1628Defining the Intensity of Conditioning Regimens:
Working Definitions
Andrea Bacigalupo, M.D.,1 Karen Ballen, M.D.,2 Doug Rizzo, M.D.,3 Sergio Giralt, M.D.,4
Hillard Lazarus, M.D.,5 Vincent Ho, M.D.,6 Jane Apperley, M.D.,7 Shimon Slavin, M.D.,8
Marcelo Pasquini, M.D.,3 Brenda M. Sandmaier, M.D.,9 John Barrett, M.D.,10
Didier Blaise, M.D.,11 Robert Lowski, M.D.,12 Mary Horowitz, M.D.3Defining conditioning regimen intensity has become a critical issue for the hemopoietic stem cell transplant
(HSCT) community. In the present report we propose to define conditioning regimens in 3 categories: (1)
myeloablative (MA) conditioning, (2) reduced-intensity conditioning (RIC), and (3) nonmyeloablative (NMA)
conditioning. Assignment to these categories is based on the duration of cytopenia and on the requirement
for stem cell (SC) support: MA regimens cause irreversible cytopenia and SC support is mandatory. NMA
regimens cause minimal cytopenia, and can be given also without SC support. RIC regimens do not fit criteria
for MA or NMA regimens: they cause cytopenia of variable duration, and should be given with stem cell sup-
port, although cytopenia may not be irreversible. This report also assigns commonly used regimens to one of
these categories, based upon the agents, dose, or combinations. Standardized classification of conditioning
regimen intensities will allow comparison across studies and interpretation of study results.
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tioningINTRODUCTION
Patients undergoing an allogeneic hemopoietic
stem cell transplant (HSCT), are prepared with che-
motherapy alone or chemotherapy combined with ra-
diotherapy, the so-called conditioning regimen, with
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6/j.bbmt.2009.07.004system, to allow engraftment of stem cells (SCs) [1].
Exceptions to this rule are infants with combined se-
vere immune deficiency (SCID) [2] and patients with
severe aplastic anemia (SAA) with an identical twin do-
nor, who may be grafted without conditioning.
The intensity of the conditioning regimen can vary
significantly. The conventional conditioning for most
young patients with leukemia/lymphoma is either
cyclophosphamide (Cy) 120 mg/kg and total body
irradiation (TBI) (10–15 Gy) (referred to as Cy-TBI)
[3] or busulfan (Bu) 16 mg/kg orally and Cy 120 mg/
kg, (referred to as Bu-Cy) [4]. Several attempts have
been made in the past 30 years to limit early transplant
toxicity, by reducing the intensity of the conditioning
regimen: John Hobbs and colleagues used half the
dose of BU (8 mg/kg) in children with inborn errors
[5]; Peter Tutchka and his coworkers [6] reduced the
dose of Cy from 200 to 120 in the classic Bu-Cy regi-
men, and Lucarelli et al. [7] reduced the dose of Bu
from 16 mg/kg to 14 mg/kg for his thalassemia condi-
tioning regimen. In contrast, some regimens were in-
tensified with the aim of reducing leukemia relapse:
the Seattle team delivered 15.75 Gy rather than 12
Gy in patients with leukemia [8]. Other investigators
introduced the use of etoposide in combination with
TBI [9]. Very few regimens have been prospectively
compared head to head, with the exception of the
Biol Blood Marrow Transplant 15:1628-1633, 2009 1629Defining the Intensity of Conditioning RegimensSeattle TBI regimens [8], and we have no evidence that
intensified conditioning improves survival: the reason
being that any decrease of leukemia recurrence with
a higher dose of TBI is achieved at the expense of in-
creased toxicity [8].
Within the past 15 years, 2 changes have occurred
in the conditioning regimens: the introduction of flu-
darabine (Flu) [10-13] and further dose reduction of
the alkylating agents [14-16] or TBI [17]. These regi-
mens were specifically designed for patients ineligible
for conventional conditioning, either because of age
(usually above 50 years) or because of the presence of
comorbidities [18]. By reducing the intensity of the
conditioning regimen, the benefit of allogeneic trans-
plantation would come from a graft-versus-malignancy
effect, rather than from the upfront cyto reductive
effect of the conditioning regimen [12]. These modi-
fied regimens have rapidly become popular, such that
by 2001 almost 30% of transplants were performed
with reduced-intensity conditioning (RIC) regimens
[19].
Regimens using Flu and/or reduced doses of
chemo/radiotherapy have been referred to as nonmye-
loablative (NMA) SC transplants, RIC transplants, or
minitransplants. Several workshops have been con-
vened on this issue: a panel of transplant physicians
on behalf of the European Group for Blood and Mar-
row Transplantation (EBMT) considered the term
minitransplant inappropriate, because it was mislead-
ing for patients, care providers, physicians, and insur-
ance companies [18]. A workshop convened by the
Center for International Blood and Marrow Trans-
plant Research (CIBMTR) addressed the dose spec-
trum, which defines an RIC regimen [20]. The
interest on defining conditioning regimens is justified
by the need of a common language in the scientific
community, and also pertains transplant registration
and documentation requirements, which are now man-
datory in several national and international regulatory
agencies.
In the present report we will discuss 3 categories of
conditioning regimens: myeloablative (MA), RIC, and
NMA. The terminology reflects the early regimen-re-
lated toxicity toward host marrow cells, and not the bi-
ologic effect of the transplant. The latter component is
complex, involving engraftment of donor lymphohema-
topoietic cells, followed by ‘‘displacement’’ of host lym-
phohematopoietic cells, through an immune-mediated
myeloablation [1].MYELOABLATIVE CONDITIONING (MA)
The term myeloablation refers to the administra-
tion of TBI and/or alkylating agents, at doses that
will not allow autologous hematologic recovery.
Over 50 years ago Lorenz and coworkers [21] showedthat mice exposed to 10 Gy of TBI would succumb to
pancytopenia. Work of Lorenz and other outstanding
investigators confirmed that animals could be rescued
by intravenous administration of a bone marrow (BM)
cell suspension [21,22]: BM transplantation (BMT)
was born and human studies were initiated [23]. Initial
attempts to apply BMT in humans were hampered by
the lack of appropriate donor-recipient matching pro-
cedures: the discovery of the human leukocyte antigen
system (HLA) initiated the widespread clinical use of
allogeneic transplants [3,4]. The agents chosen to pre-
pare humans for BMT were TBI, Cy, and Bu, at the
dose used in animals: TBI 10 Gy, Cy 200 mg/kg [3]
and BU 16 mg/kg [4]. The combinations of Bu-Cy
or Cy-TBI are considered to be an MA conditioning
regimen. Other agents have been introduced in the
conditioning regimen at high doses, and in different
combinations with Cy or TBI, usually with the inten-
tion of further intensification: these include melphalan
(MEL) [24], thiotepa (THIO) [10], etoposide (VP16)
[25], and dimethylbusulfan [26].
MA regimens usually produce rapid engraftment of
donor cells, which may be followed in a proportion of
patients, by graft-versus-host disease (GVHD). MA
regimens are associated with toxicity and mortality—
referred to as treatment-related mortality (TRM)—
depending on variables such as patient age, donor
age, donor/recipient HLA matching, sex matching,
phase of the underlying disease (early or advanced),
and year of transplant. The risk of TRM after a MA reg-
imen has decreased over time, although the exact rea-
son for improvement is not entirely clear [27]. It most
probably relates to improved HLA-matching technol-
ogy, in the unrelated donor setting, and better support-
ive care. Patients with early leukemia seem to have most
benefited of this improvement [27].
Cure of the underlying disease depends in part on
the intensity of the MA regimen [1]: this was proved in
a prospective randomized trial showing that TBI 15.75
Gy was associated with a lower risk of relapse com-
pared to TBI 12 Gy [8]. However, patients receiving
the higher dose of TBI also had a higher incidence of
GVHD ,thus, making unclear the relative contribution
of the TBI to the lower risk of relapse. Other retro-
spective studies have confirmed the impact of condi-
tioning intensity on relapse [9]. Unfortunately, the
higher TBI dose was also associated with a higher
risk of TRM, so that survival was comparable in the
2 groups [8]. The antileukemia effect of MA regimens
can be further enhanced with the use of targeted radio-
immunoconjugates [28], which would, in theory, not
increase regimen-related toxicity. However, because
the use of these agents in the context of conditioning
regimens remains investigational, their exact place in
the intensity spectrum is unknown.
It should be noted that it is probably impossible to
‘‘myeloablate’’ completely an animal or an individual
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have been reported after high-dose chemotherapy or
accidental exposure to radiation [30,31]. Therefore,
the term MA should be considered an operational def-
inition, indicating a regimen causing irreversible pan-
cytopenia in almost all patients: autologous recovery
(at best following prolonged life-threatening cytope-
nia) would be the exception.
Definition of MA regimen: a combination of agents ex-
pected to produce profound pancytopenia and myeloablation
within 1-3weeks fromadministration; pancytopenia is long
lasting, usually irreversible, and in most instances fatal,
unless hematopoiesis is restored by hemopoietic stem cell
infusion
Examples of MA regimens are shown in Table 1.
A workshop was convened at a CIBMTR/ASBMT
meeting to assess whether expert transplanters would
agree on what is considered an MA regimen [20].
The regimens listed in Table 1 obtained a general
consensus.NMA CONDITIONING REGIMENS
TRM after MA regimens increases with increasing
patient age, and 50 years used to be considered an
upper age limit [25]. With the aim of reducing toxicity,
thus making transplantation available in the older
patient population, so-called NMA conditioning regi-
mens were developed. Examples of NMA regimens
include: Flu-Cy [32], TBI 2 Gy [17], TBI 1 Gy [33], to-
tal lymphoid radiation (TLI), and antithymocyte glob-
ulin (ATG) [34]. NMA typically cause minimal
cytopenia, and little early toxicity, but are immunosup-
pressive to the extent that, when followed by granulo-
cyte-colony stimulating factor (G-CSF) mobilized
peripheral blood stem cells (PBSCs), they usually re-
sult in full engraftment of donor lymphohemopoietic
SCs. A good example is the Flu-Cy combination devel-Table 1. Example of Myeloablative and Nonmyeloab-
lative Regimens According to Commonly Used Agents and
Combinations
Myeloablative (MA)*
TBI $5 Gy single dose or $8 Gy fractionated
Bu >8 mg/kg orally or intravenous equivalent
Nonmyeloablative (NMA)†
TBI #2 Gy± purine analog
Flu + Cy ± ATG
Flu +AraC + Ida
Cladribine + AraC
Total Lymphoid Irradiation + ATG
AraC indicates cytarabine; ATG, antithymocyte globulin; Bu, busulfan;
Gy, grays; Cy, cyclophosphamide; Flu, fludarabine; Ida, idarubicin; TBI,
total body irradiation.
Reduced-intensity regimens (RIC) are regimens that do not fit these two
categories; examples of these regimens in the text.
*See [1].
†See [12,17,32-34].oped in Houston for the treatment of chronic lympho-
cytic leukemia (CLL): the same regimen followed
by mobilized allogeneic PBSC, results in donor
engraftment [30]. In addition to myeloablation, we
introduce here the concept of immunoablation. NMA
are immunoablative regimens, and this is why donor
cells engraft. However, NMA also require a large num-
ber of donor T lymphocytes and donor CD341 cells,
to facilitate donor engraftment. It is therefore the
combination of immunoablation and large numbers of
donor cells that constitute the essence of NMA pro-
grams [33]. These transplants are followed by low early
toxicity, despite older patient age and greater number
of patients with comorbidity [35]. TRM is lower after
NMA compared to MA regimens [35].
Acute GVHD (aGVHD) after NMA is delayed,
and may develop after day 100, at a time when chronic
GVHD (cGVHD) is usually diagnosed after an MA
regimen [36]. GVHD remains a significant cause of
morbidity and mortality also after NMA [36]. NMA
have been explored in patients with leukemia [37]
lymphoma [32], myeloma [38], and solid tumors [39].
Definition of NMA regimen: a regimen that will cause
minimal cytopenia and does not require stem cell sup-
port.
This is an operational definition: indeed, only
some of the regimens classified as NMA are truly non-
ablative, such as the Flu-Cy or TLI-ATG. On the
other hand, TBI also at low doses causes some degree
of ablation of the SC reservoir. But because TBI 1 or 2
Gy do not cause cytopenia and can be given without
SC support, they can be defined as NMA. In addition,
NMA refers only to the conditioning regimen: in
fact, the transplant, as a procedure, is MA, because en-
grafted donor T cells will eventually eliminate host he-
mopoietic cells, allowing the establishment of donor
hematopoiesis.
Examples of NMA regimens are shown in Table 1.RIC REGIMENS
RIC regimens is an intermediate category of regi-
mens that do not fit the definition for MA or NMA.
RIC regimens differ from NMA: they cause cytopenia,
which may be prolonged, and do require stem cell
support. It is possible that autologous recovery would
eventually occur, although pancytopenia would be
of such duration to cause significant morbidity and
mortality.
RIC regimens differ from MA conditioning, because
the dose of alkylating agents or TBI is reduced by at
least 30%. Most often these regimens combine Flu
with an alkylating agent, melphalan (Mel) [40], Bu
[14], thiotepa [15] in reduced doses, or Flu with re-
duced-dose TBI [41]. TRM is reduced after RIC
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Figure 1. Classification of conditioning regimens in 3 categories, based
on duration of pancytopenia and requirement for stem cell support.
Myeloablative fregimens (MA) produce irreversible pancytopenia and
require stem cell support. Non myeloablative regimens (NMA) produce
minimal cytopenia and does not require stem cell support. Reduced in-
tensity regimens (RIC) are regimens which can not be classified as MA
nor NMA.
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comparing RIC and MA regimens [42-45]. RIC pro-
grams require SCl support to be practical in the clinic:
RIC regimens have used a wide selection of agents,
given at a wide range of doses RIC regimens have
been explored in patients with acute and chronic leuke-
mia, lymphoma, myeloma, and patients with myelo-
dysplastic syndromes (MDS), as shown by large
Registry-based studies [42,46].
For some conditioning regimens, classification
may be not straightforward. One example is Cy 200
mg/kg, with or without thymic radiation [47,48].
This is a truly nonablative regimen, because it does
not kill SCs, but it does cause profound cytopenia, es-
pecially when given over 4 days (50 mg/kg/day 4) in
patients with SAA, and is followed by allogeneic hemo-
poietic SC. Some of these patients may recover an au-
tologous hematopoies, and Cy 200 mg/kg has also
been given in aplastic anemia, without SC support
[49], although the rate of lethal infections, because of
prolonged cytopenia, was very high [50]. Therefore,
Cy 200 mg/kg does not fit our working definition of
a MA conditioning nor of a NMA conditioning, and
falls in the category of RIC conditioning.
Definition of a RIC regimen: a regimen that cannot be
classified as NMA or MA.CONCLUSION
We propose to define the intensity of the condi-
tioning regimen on the basis of the duration ofpancytopenia induced and on the requirement for SC
support, as shown in Figure 1.
An MA conditioning regimen will cause irreversible
(or close to irreversible) pancytopenia. SC support
is required to rescue marrow function, and prevent
aplasia-related death.
An NMA regimen (NMA) is a regimen that will
produce minimal cytopenia, and there is no need for
SC support.
A conditioning regimen that does not fulfill MA or
NMA is defined as an RIC regimen.
These definitions should be regarded as a starting
point, which may be rediscussed in the near future.
The notion of the 2 conventional MA regimens
(Cy-TBI and Bu-Cy) is well established. The concept
of NMA regimens, is also clear, and based on agents, or
combination of agents, producing minimal cytopenia.
All other regimens should be called RIC, not because
they are Flu based, but rather because they do not fit
criteria for MA or NMA regimens.
Adoption of a classification for preparative regi-
mens in 3 different categories would be important
for crossreferencing in the scientific literature. The
inclusion of new agents in conditioning regimens,
such as disease specific drugs or targeted therapies
with monoclonal antibodies, will need to be incorpo-
rated in the intensity spectrum. This classification
and terminology, if adopted by the transplant commu-
nity, will serve as a starting point to standardize these
transplant modalities, and facilitate interpretation of
retrospective studies and development of prospective
trials.ACKNOWLEDGMENTS
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